Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Accumulated Depreciation (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Accumulated Depreciation data on record, last reported at $5.0 million in Q3 2025.

  • For Q3 2025, Accumulated Depreciation changed N/A year-over-year to $5.0 million; the TTM value through Sep 2025 reached $5.0 million, changed N/A, while the annual FY2024 figure was $4.8 million, 15.45% up from the prior year.
  • Accumulated Depreciation reached $5.0 million in Q3 2025 per ACRS's latest filing, down from $5.0 million in the prior quarter.
  • Across five years, Accumulated Depreciation topped out at $5.0 million in Q2 2025 and bottomed at $3.0 million in Q2 2021.
  • Average Accumulated Depreciation over 5 years is $4.2 million, with a median of $4.3 million recorded in 2023.
  • Peak YoY movement for Accumulated Depreciation: increased 29.36% in 2021, then rose 3.15% in 2023.
  • A 5-year view of Accumulated Depreciation shows it stood at $3.4 million in 2021, then increased by 18.92% to $4.0 million in 2022, then increased by 3.15% to $4.2 million in 2023, then increased by 15.45% to $4.8 million in 2024, then rose by 3.73% to $5.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation were $5.0 million in Q3 2025, $5.0 million in Q2 2025, and $4.8 million in Q4 2024.